RecruitingNot Applicable

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma

China89 participantsStarted 2023-12-06

Plain-language summary

A prospective, open-abel, phase 2 clinical study to investigate whether interim Positron Emission Tomography (PET) and Epstein-Barr virus (EBV) DNA-directed therapy can improve the prognosis of localized nasal extranodal NK/T cell lymphoma (ENKTL) patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Absolute neutrophil count (ANC)\> 1000 / μL, platelet count\> 50, 000 / μl, hemoglobin\> 9g/ dl;
✓. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<3 times the upper limit of normal (ULN); Serum total bilirubin \<1. 5 times ULN (patients with Gilbert syndrome can be included);
✓. Serum creatinine \<2 times ULN or creatinine clearance rate\> 50 ml/min.

What they're measuring

2-year progression-free survival rate

Timeframe: Baseline up to data cut-off (up to approximately 2 years)

Trial details

NCT IDNCT06069830

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10

Contact for this trial

Weili Zhao

+862164370045 zwl_trial@163.com

View on ClinicalTrials.gov More NK-T-Cell Lymphoma, Extranodal trials